A refractory heterogeneous Cryopyrin-Associated Periodic Syndrome (CAPS) phenotype related to V198M mutation responds to canakinumab - a case report

Benzer Materyaller

• Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians
  Yazar:: Kuemmerle-Deschner, Jasmin B., ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• Diagnosis and Management of the Cryopyrin-Associated Periodic Syndromes (CAPS): What Do We Know Today?
  Yazar:: Welzel, Tatjana, ve diğerleri
  Baskı/Yayın Bilgisi: (2021)
• Long-term safety and efficacy of Canakinumab in cryopyrin-associated periodic syndrome (CAPS) patients: results from beta-confident registry
  Yazar:: Kuemmerle-Deschner, J, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Induction of Myeloid-Derived Suppressor Cells in Cryopyrin-Associated Periodic Syndromes
  Yazar:: Ballbach, Marlene, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)
  Yazar:: Kuemmerle-Deschner, Jasmin B, ve diğerleri
  Baskı/Yayın Bilgisi: (2011)